{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:31:11Z","timestamp":1770280271363,"version":"3.49.0"},"reference-count":11,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Dermatol"],"abstract":"<jats:p>Introduction: We provide a case report on a patient with scleromyxedema treated with high-dose intravenous immunoglobulins (IVIgs) who reported less fatigue and fewer headaches after transitioning to Yimmugo, a novel IVIg preparation. Scleromyxedema is a rare and chronic cutaneous mucinosis, frequently associated with monoclonal gammopathy and systemic complications, which may be life-threatening. The disease is characterized by papular eruptions and sclerosis of the skin. Treatment of scleromyxedema is challenging because of its unclear pathogenesis. High-dose IVIgs are a promising treatment option to improve cutaneous manifestations. Case Presentation: We present the case of a 57-year-old patient with scleromyxedema and monoclonal gammopathy with end-stage renal failure on hemodialysis (3 times a week). Stabilization of skin symptoms was finally achieved by high-dose IVIg therapy administered at 2 g per kg bodyweight distributed over 2 days every 3 weeks. However, disease stabilization came at the expense of flu-like side effects that significantly affected daily life. After transitioning to Yimmugo\u00ae, the patient reported an improved quality of life. Conclusion: Further follow-up is essential to conclusively evaluate effectiveness and tolerability of this novel IVIg preparation. <\/jats:p>","DOI":"10.1159\/000540519","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T09:21:38Z","timestamp":1725441698000},"page":"210-215","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of a Complex Case of Scleromyxedema Using a Novel Intravenous Immunoglobulin Preparation"],"prefix":"10.1159","volume":"16","author":[{"given":"Anastasia Sophie","family":"Vollmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Wiedenmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia K.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander H.","family":"Enk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14319"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14888"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm2302207"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.111630"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01090"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/9781119719809.ch22"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-023-00430-w"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2165\/11537660-000000000-00000"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.09.002"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01299"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0900"}],"container-title":["Case Reports in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/cde\/article-pdf\/16\/1\/210\/4271447\/000540519.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/cde\/article-pdf\/16\/1\/210\/4271447\/000540519.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:32:36Z","timestamp":1745422356000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000540519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,17]]}},"URL":"https:\/\/doi.org\/10.1159\/000540519","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.26484532","asserted-by":"subject"}]},"ISSN":["1662-6567"],"issn-type":[{"value":"1662-6567","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}